<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">The primary ZIKV vectors, 
 <italic>Aedes aegypti</italic> and 
 <italic>Aedes albopictus</italic>
 <sup>
  <xref ref-type="bibr" rid="CR2">2</xref>,
  <xref ref-type="bibr" rid="CR3">3</xref>,
  <xref ref-type="bibr" rid="CR29">29</xref>
 </sup>, also transmit chikungunya virus (CHIKV) and DENV. In contrast to CHIKV (an alphavirus), DENV and ZIKV are genetically similar flaviviruses
 <sup>
  <xref ref-type="bibr" rid="CR8">8</xref>
 </sup>. DENV exists as four antigenically distinct serotypes (DENV1-4). When an individual is infected by DENV, there is a period of cross-protection from infection by other serotypes
 <sup>
  <xref ref-type="bibr" rid="CR30">30</xref>
 </sup>. After the period of cross-protection, subsequent infections with different serotypes can result in more severe disease due to antibody dependent enhancement (ADE)
 <sup>
  <xref ref-type="bibr" rid="CR31">31</xref>,
  <xref ref-type="bibr" rid="CR32">32</xref>
 </sup>. It has been speculated that, due to the similarity between DENV and ZIKV, immunity to one of these viruses may alter the chance of infection or probability of severe disease following exposure to the other virus. Current evidence supports both the potential for enhancement
 <sup>
  <xref ref-type="bibr" rid="CR4">4</xref>–
  <xref ref-type="bibr" rid="CR7">7</xref>
 </sup> and for cross-protection
 <sup>
  <xref ref-type="bibr" rid="CR5">5</xref>,
  <xref ref-type="bibr" rid="CR7">7</xref>–
  <xref ref-type="bibr" rid="CR10">10</xref>
 </sup>.
</p>
